Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17085390 | 0.86 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1CA2CHKALOXL2 | |
| Hydrochloric Acid SCHEMBL17079135 | 0.85 | LOXL2 (0.40) | HSP90AA1HSP90AB1CA2CHKALOXL2 | |
| SCHEMBL19004924 | 0.82 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1CA2CHKALOXL2 | |
| Bromide SCHEMBL18985550 | 0.81 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1CA2CHKALOXL2 | |
| SCHEMBL6120892 | 0.78 | RECQL (0.41) | HSP90AA1HSP90AB1LOXL2KDM4EALDH1A1 | |
| SCHEMBL21597028 | 0.78 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1LOXL2KDM4EALDH1A1 | |
| SCHEMBL31039227 | 0.78 | RECQL (0.41) | HSP90AA1HSP90AB1LOXL2KDM4EALDH1A1 | |
| SCHEMBL17079130 | 0.77 | PTGS2 (0.42) | HSP90AA1HSP90AB1KDM4EALDH1A1KMT2A | |
| SCHEMBL28573934 | 0.77 | LOXL2 (0.36) | HSP90AA1HSP90AB1CA2CHKALOXL2 | |
| SCHEMBL18050066 | 0.77 | TSHR (0.40) | HSP90AA1HSP90AB1LOXL2KDM4EPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390387-B1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3390387-B1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2021-11-17 | — | — | EP | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| EP-3390387-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | disclosed |
| US-9856242-B2 | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group | BAYER PHARMA AKTIENGESELLSCAFT (DE) | 2018-01-02 | — | — | US | disclosed |
| US-9856242-B2 | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group | BAYER PHARMA AKTIENGESELLSCAFT (DE) | 2018-01-02 | — | — | US | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
| EP-3116869-A1 | 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | Bayer Pharma Aktiengesellschaft (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-20170001989-A1 | 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20170001989-A1 | 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20170001989-A1 | 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-05 | — | — | US | disclosed |
| CN-106232596-A | 5 fluorine N (pyridine 2 base) pyridine 2 amine derivative containing sulfone group | 拜耳医药股份有限公司 | 2016-12-14 | — | — | CN | disclosed |
| WO-2015136028-A1 | 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | HSP90AA1 2647/4885HSP90AB1 1602/4885CA2 4378/4885 |
| US-20170001989-A1 | 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | PNPO, PAH, TPMT | HSP90AA1 3364/4885HSP90AB1 2566/4885CA2 4503/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | HSP90AA1 2647/4885HSP90AB1 1602/4885CA2 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.